Provided by Tiger Trade Technology Pte. Ltd.

Tscan Therapeutics, Inc.

0.7795
+0.00330.43%
Post-market: 0.77950.00000.00%19:30 EDT
Volume:136.16K
Turnover:106.31K
Market Cap:52.83M
PE:-0.87
High:0.7900
Open:0.7900
Low:0.7718
Close:0.7762
52wk High:2.57
52wk Low:0.7160
Shares:67.78M
Float Shares:57.82M
Volume Ratio:0.40
T/O Rate:0.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9000
EPS(LYR):-2.2805
ROE:-95.80%
ROA:-31.53%
PB:0.77
PE(LYR):-0.34

Loading ...

Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of Tsc-101 for Patients With Hematologic Malignancies

THOMSON REUTERS
·
Jun 03

TScan Therapeutics - Agreement Adds Tcr-T Cell Therapies to Cellares Automated Portfolio

THOMSON REUTERS
·
Jun 03

TScan Therapeutics Expands Authorized Shares After Stockholder Vote

TIPRANKS
·
May 23

TScan Therapeutics shareholders approved voting common stock authorization increase to 600 million shares

Reuters
·
May 23

H.C. Wainwright Sticks to Their Buy Rating for TScan Therapeutics (TCRX)

TIPRANKS
·
May 07

TScan Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 06

TScan Q1 net loss narrows to $28.7 million; revenue drops to $1 million

Reuters
·
May 06

TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
May 06

TScan Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview

Reuters
·
May 01

TScan Therapeutics to present ASGCT meeting poster on CD45-targeted TCR-T therapies

Reuters
·
Apr 28

TScan Therapeutics announces annual shareholder meeting webcast

Reuters
·
Apr 08

TScan Therapeutics Consolidates Finance Leadership After Officer Resignation

TIPRANKS
·
Apr 02

TScan VP Finance Dworak resigns; CFO Amello named principal accounting officer

Reuters
·
Apr 02

TScan Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 04

TScan Therapeutics Q4 net loss widens

Reuters
·
Mar 04

TScan posts Q4 net loss of USD 23.0 million (35.8%)

Reuters
·
Mar 04

TScan Therapeutics Q4 Income From Operations USD -23.858 Million

THOMSON REUTERS
·
Mar 04

TScan Therapeutics Q4 Net Income USD -22.977 Million

THOMSON REUTERS
·
Mar 04

TScan Therapeutics Inc: Cash and Cash Equivalents Continue to Fund Operations Into Second Half of 2027

THOMSON REUTERS
·
Mar 04

TScan Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Reuters
·
Mar 02